Skip to main content
snıff

Comparative oncology · reverse-lookup · candidate

Insulinoma

Human insulinoma has known somatic drivers. No one has sequenced the canine tumors. So this asks the honest reverse question: dogs carry the ortholog of each human driver, which makes them candidate models, and the fact that no canine tumor has been characterized is itself the finding worth naming.

The gap (unstudied)

No canine insulinoma tumor has ever been sequenced for somatic drivers. The published canine literature is transcriptomic and clinical only (Capodanno 2020 RNA-seq n=9; Capodanno 2022 review). So whether the human insulinoma drivers below also drive the canine disease is UNKNOWN. This is a candidate model and a documented gap, not a canine finding.

Human driver, dog ortholog, canine status

Each human driver of insulinoma (cohort-cited), the dog ortholog we hold for it, and the honest canine status. A candidate is not a verdict: the dog carrying the gene is not the dog getting the mutation.

YY1 insulinoma-specific neomorphic driver (T372R hotspot) human 25% of 84 · Hong et al. 2020
dog ortholog held · 98.31% id canine population variation present canine tumor: unsequenced

THE human insulinoma driver: 25% (21/84, Hong 2020), insulinoma-specific (0/127 non-functional pNET). Dogs carry a one2one YY1 ortholog at 98.3% protein identity, but YY1/T372R has NEVER been assessed in canine insulinoma. This is the single largest translational-genomic gap for the canine model.

MEN1 tumor suppressor (menin); the insulinoma-vs-pNET contrast human 2% of 84 · Hong et al. 2020
dog ortholog held · 96.39% id canine population variation present canine tumor: unsequenced

Low in human insulinoma (~2%) unlike non-functional pNET (42 to 45%), the key human distinction; Capodanno 2022 states MEN1 is qualitatively not involved in canine insulinoma either. Dog ortholog held (one2one, 96.4% identity). Canine tumor status otherwise unsequenced.

PTEN mTOR-pathway tumor suppressor (pathway relevant) human rate abstained
dog ortholog held · 100% id canine tumor: unsequenced

The mTOR pathway is altered in a subset of pancreatic neuroendocrine tumors; the insulinoma-specific PTEN frequency is not separately tabulated, so it abstains. Capodanno 2020 saw the PI3K pathway upregulated in canine insulinoma metastases at the EXPRESSION level only (RNA-seq, not a somatic mutation). Dog ortholog held at 100% identity; the human gene carries germline ClinVar disease evidence.

PIK3CA mTOR/PI3K-pathway oncogene (pathway relevant) human rate abstained
dog ortholog held · 99.81% id canine population variation present canine tumor: unsequenced

A PI3K-pathway node relevant to the mTOR axis in pancreatic neuroendocrine tumors; insulinoma-specific frequency abstains. Dog ortholog held (one2one, 99.8% identity). PIK3CA is a shared driver in other canine cancers (mammary, hemangiosarcoma), which is exactly the kind of cross-cancer link this bridge makes visible.